© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
Kadcyla reduces the risk of breast cancer recurring and spreading after surgery.
Women who had breast-conserving surgery rather than mastectomy report better quality of life.
The new trials compare the two approaches to treating women with early-stage breast cancer with long-term follow-up.
Experts say Kadcyla should become a new standard of care for adjuvant therapy.
Additional research is required to determine the basis for these racial disparities.
Alpelisib showed greater benefit in patients selected with a liquid biopsy test.
Study supports incorporating supervised exercise programs into breast cancer treatment guidelines.
Waiting more than 30 days after surgery was associated with worse outcomes.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
